Atherosclerosis remains a major problem in modern society being a cause of life-threatening cardiovascular diseases.The development of atherosclerosis is characterized by lipid accumulation in the aortic wall and the formation of foam cells overloaded with large amounts of lipid inclusions in the cytoplasm. This is one of the main causes of cardiac ischemia, peripheral vascular disease, and heart failure is the result of endothelial cell injury and damage. The endothelial damage results in the formation of plaque, narrowing of the arteries, and thickening of the arterial wall by cholesterol accumulation. Hence the present study was made to investigate the Cyheart against atherosclerosis. The present study was made with the following objectives: MTTviability assay, Atherosclerotic markers Metalloproteinase 2 (MMP2), ApoE(Apolipoproteins), and Interleukin 6 (IL6) were used for gene expression study of Antiatherosclerotic effect of CYHEARTand Quantitative analysis of endogenous nitric oxide (NO)in human endothelial cells with CYHEART using Griess assay. We observed the dose-dependent viability of Endothelial cells,implying-toxic nature of ���CYHEART��� even at higher doses(100��g/ml) by retaining cellular morphology(disrupted in Standard drug Ecosprin Gold). Further, the dose-dependent NO (Endogenous nitric oxide) release was observed. It is higher at100��g/ml concentration demonstrating the anti-atherosclerotic effect of ���CYHEART ���compared to control and standard.A significant increase in relative gene expression of specific anti-atherosclerotic marker ApoE exemplifies the effective anti-atherosclerotic effect of ���CYHEART���.The studies Conclude CY HEART PREMIUM HEALTH TONIC has anti-atheroscleroticandCardioprotective effects which are equal or more effective than standard Ecosprin Gold 10